Published in final edited form as:

Curr Opin Chem Biol. 2008 August ; 12(4): 434–440. doi:10.1016/j.cbpa.2008.06.033.

Advances in and applications of proteasome inhibitors

Bradley S. Moore^{*}, **Alessandra S. Eustáquio**, and **Ryan P. McGlinchey**

Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, and the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, La Jolla, CA 92093

Summary

With the recent US Food and Drug Administration approval of bortezomib (Velcade®) for the treatment of relapsed multiple myeloma, the proteasome has emerged as a new therapeutic target with diverse pathology. Drug discovery programs in academia and the pharmaceutical industry have developed a range of low nanomolar synthetic and natural inhibitors of the 20S proteasome core particle that have entered human clinical trials as significant anti-cancer and anti-inflammatory leads. Moreover, proteasome inhibitors continue to serve as valuable research tools in cellular biology through the elucidation of important biological processes associated with the ubiquitin-proteasome pathway of protein degradation. This review will highlight recent advances in the development and application of proteasome inhibitors.

Introduction

The ubiquitin-proteasome pathway in eukaryotes regulates many normal cellular processes including signal transduction, cell cycle control, transcriptional regulation, inflammation, and apoptosis through protein degradation and the maintenance of protein homeostasis [1–3]. This primary route of regulated proteolysis of bulk and misfolded protein in mammalian cells is strictly controlled by the 26S proteasome complex, which recognizes polyubiquitinated proteins marked for elimination by the E1, E2, and E3 ubiquitinating enzymes (Fig. 1). Upon recognition, unfolding and transfer of the de-ubiquitinated target protein by the 19S regulatory cap into the interior of the cylindrical 20S proteasome core particle, protein degradation is facilitated by catalytic β -subunits having nucleophilic *N*-terminal threonine (Thr1) residues. Although eukaryotic 20S proteasomes harbor seven different β -subunits in their twofold symmetrical $\alpha_7\beta_7\beta_7\alpha_7$ stacked complexes, only three β -subunits per β -ring [subunits $\beta 1$ (caspase-like), $\beta 2$ (trypsin-like), and $\beta 5$ (chymotrypsin-like)] are proteolytically active (Fig. 1). The disruption of this degradative process with small molecule inhibitors against one or more catalytic β -subunit has implications in a number of human diseases such as cancer, inflammation, and ischemic stroke and has exposed the proteasome as an important therapeutic target [4–7].

Chemical classes of proteasome inhibitors

The nucleophilic character of the proteasome is governed by the active site Thr1 residue of each catalytic β -subunit in which the side chain hydroxyl group reacts with peptide bonds of

^{*}Corresponding author: Bradley S. Moore, bsmoore@ucsd.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

substrates as well as with electrophilic functional groups of inhibitors. Selectivity is dictated by the composition of the substrate binding pockets (termed S1, S2, Sn and S1', S2', Sn' depending on proximity to the active site), which differs in the three catalytic β -subunits. A wide range of specific inhibitors has been developed as mechanism-based synthetic peptidyl electrophiles and natural products with IC₅₀ values in the low nanomolar range [8].

Tripeptide aldehydes such as the calpain inhibitor I (Ac-Leu-Leu-nLeu-al) and actinomycete natural product leupeptin (Ac-Leu-Leu-Arg-al) were the first class of inhibitors to probe the biochemistry of the proteasome active sites [9] and reveal that the proteasome belongs to a novel class of *N*-terminal threonine proteases [10]. While the peptide aldehydes form reversible covalent hemiacetal intermediates with Thr1O^γ primarily of the β 5-subunit, their moderate reactivity (low micromolar) and lack of *in vivo* specificity (also inhibit serine and cysteine proteases) led to the exploitation of other binding head groups with greater potency and selectivity. Diverse functional groups such as vinyl sulfones [11], boronates [12] and natural product-based α' , β' -epoxyketones [13] were explored and provided a number of important leads.

Peptide boronates, which are aldehyde surrogates, are much more reactive with sub-nanomolar potency and are selective towards the proteasome over common proteases [12]. Due to their high selectivity, potency and low dissociation rates, the peptide boronates are ideal candidates for drug development, and many analogs have been prepared and evaluated. The dipeptide boronic acid bortezomib (Velcade®, PS-341) (Fig. 2), a reversible inhibitor of the β 5-subunit, is the first in class proteasome inhibitor approved by the US Food and Drug Administration for the treatment of relapsed multiple myeloma and mantle cell lymphoma [14]. Recently, the boronate derivative CEP-18770 harboring a threonine residue was advanced to preclinical development due to its oral bioavailability and bortezomib-like pharmacology [15,16].

Irreversible non-aldehydic peptide inhibitors include the vinyl sulfones and the α' , β' -epoxyketones. While synthetic vinyl sulfones suffer from a lack of specificity, natural epoxyketone peptides such as epoxomicin (Fig. 2) [13] are highly selective, potent and irreversible inhibitors of the proteasome. Numerous peptidyl epoxyketones bearing various chain lengths of acylated di- to tetra-peptides have been characterized from actinomycetes that primarily interact with the β 5-subunit. Epoxomicin has a distinct mechanism of action in which the inhibitor forms a unique morpholino ring system between the epoxyketone functional group and Thr1 [17]. The significance of this mechanism provides epoxomicin's unique specificity for the proteasome, since other proteases do not have an *N*-terminal nucleophilic residue as part of their active sites. Hence, epoxomicin is unable to form the same stabilized morpholino adduct with proteases as it does with the proteasome. A synthetic analog of epoxomicin, PR-171 [18], which irreversibly inhibits the β 5-subunit of the proteasome, is currently in phase I human clinical trials for the treatment of multiple myeloma and non-Hodgkin's lymphoma.

Since the discovery of bortezomib resistance in multiple myeloma cells, the natural product β -lactones have gained widespread attention as second generation drug candidates. The streptomycete metabolite lactacystin was the first natural non-peptidic proteasome inhibitor [19]. Its low nanomolar reactivity toward the proteasomal β 5-subunit is dependent on its transformation to *clasto*-lactacystin- β -lactone (omuralide) with concomitant loss of *N*-acetylcysteine (Fig. 2) [20]. Nucleophilic attack of Thr1O^γ on the β -lactone functional group generates a stable covalent adduct. Crystalization studies revealed that the side chain residues of omuralide play a significant role in the selectivity of the inhibitor to the proteasome and that they were important for prolonging its noncovalent binding in the active site to allow for covalent capture due to its less reactive β -lactone functional group. The most clinically advanced lactacystin analog is PS-519 [21], a variant that features an n-propyl substitution at

C7 (Fig. 2). PS-519 is more potent than the natural product and is currently in clinical trials for acute stroke.

Recently new natural products related to omuralide that share its γ -lactam- β -lactone core yet have distinct substitution patterns have been discovered from actinomycetes with enhanced potency and selectivity (Fig. 2). Salinosporamide A (NPI-0052) from the marine actinomycete *Salinispora tropica* [22,23] is currently in phase I human clinical trials for the treatment of multiple myeloma and other cancers. Studies of this natural product have shown enhanced potency over omuralide against the chymotrypsin-like proteasome activity (IC₅₀ values of 1.3 nM versus 49 nM, respectively [22]) as well as extended activity against the other catalytic subunits. The deschloro analog salinosporamide B [24], which is ten times less potent against the proteasome *in vitro*, first suggested that the chloro substituent in salinosporamide A is mechanistically important as later demonstrated structurally in complex with the yeast 20S proteasome (see next section). Other potent analogs of salinosporamide A include the synthetic salinosporamide-omuralide hybrid 'antiprotealide' [25,26] and the bioengineered product fluorosalinosporamide [27], which is the most potent salinosporamide analog showing reversible binding activity. The most recent additions to this structural class are the cinnabaramides, which were isolated from a terrestrial streptomycete [28]. These structural analogs, which only differ from the salinosporamides in the C2 alkyl side chain, have comparable potency *in vitro* with IC₅₀ values in the low nanomolar range. It remains, however, to be shown if the cinnabaramides have the same anticancer properties as salinosporamide A.

Further proteasome inhibitors of the β -lactone family include belactosines A and C (Fig. 2) from *Streptomyces* sp. UCK14 that selectively inhibit the β 5-subunit of the proteasome, with the modified homobelactosin C derivative (Fig. 2) having an IC₅₀ in the low nanomolar level [29]. Other natural proteasome inhibitors include the TMC-95 family of cyclic peptides from the fungus *Apiospora montagnei* [30], with TMC-95A being the only natural product inhibitor to non-covalently block all active sites of the proteasome selectively and competitively in the low nanomolar range [31].

The majority of the most potent natural proteasome inhibitors are derived from actinobacteria, which are uncommon amongst prokaryotes to synthesize a 20S proteasome complex. The simplified actinobacteria proteasome is composed of identical α and β subunits with an $\alpha_7\beta_7\beta_7\alpha_7$ -stoichiometry and no regulatory caps reflective of the absence of ubiquitin in bacteria. While the mechanism for self-resistance in these bacteria that produce proteasome toxins has not yet been clarified, the recent first biosynthetic gene cluster analysis of the natural proteasome inhibitor salinosporamide A revealed an associated β -subunit that may be involved with resistance [32]. It will be intriguing to learn if other biosynthetic gene clusters associated with actinomycete proteasome inhibitors also harbor proteasome β -subunits, and if so, whether this genetic signature may enable the discovery of new inhibitor classes.

Molecular mechanism of action

High-resolution crystal structures of the 20S proteasome (mainly from yeast) in complex with all of the major inhibitors have been solved by Groll and co-workers [8]. These analyses illuminated their binding mode and mechanism of action at the molecular level and have been instrumental in the structure-based design of new inhibitors. Most proteasome inhibitors bind covalently to the catalytic Thr1 residue in the β 5-subunit with the exception of the cyclic peptide TMC-95, which shows noncovalent binding in each catalytic subunit. Recent crystal structures of the yeast 20S proteasome with bound bortezomib [33] and salinosporamide A [34] have been reported and illustrate some of the guiding principles in proteasome inhibition (Fig. 3).

As opposed to the reversible binding mode of bortezomib, binding of salinosporamide A to the proteasome has been shown to be irreversible [35,36]. Moreover, bortezomib and

salinosporamide A differentially affect proteasome activities, i.e. at low concentrations salinosporamide A preferentially targets the chymotryptic ($\beta 5$) and tryptic ($\beta 2$) while bortezomib affects chymotryptic and caspase-like ($\beta 1$) subunits [35].

The boronic acid moiety of bortezomib forms a (pseudo)covalent bond to the nucleophilic hydroxyl side chain of Thr1. Further important interactions are summarized in Figure 3a. The inhibitor occupies specificity pockets S1, S2 and S3 (Fig. 3c), which differ in charge and overall architecture depending on the subunit in question. Selectivity for the various proteasome active sites is controlled by P1 (leucine boronic acid moiety) and P3 (pyrazine-2-carboxyl group), while P2 (phenylalanine group) makes no contacts with the protein so that S2 pockets in all active sites can accept larger substituents. The leucine side chain induces a fit to Met45 of $\beta 5$ involved in key proteasome–substrate interactions and the concerted movements generated upon binding allow additional hydrophobic contacts between P1 and S1. In contrast, P1 does not interact with the larger S1 pocket in $\beta 2$. Furthermore, the S3 pocket of $\beta 2$ fundamentally differs from $\beta 5$ explaining bortezomib's lack of tryptic-like inhibitory activity. In case of $\beta 1$, Asp114 in S3 (Fig. 3a) is replaced by a histidine preventing interaction with P3 and vindicating the lower affinity for the caspase-like subunit [33]. Figure 3e depicts bortezomib's binding mechanism.

As reported for omuralide, salinosporamide A is linked to the Thr1-hydroxyl of proteasome active sites by an ester bond with the carbonyl carbon of the β -lactone [34] (Fig. 3b). However, while omuralide occupies only $\beta 5$ subunits, salinosporamide A interacts with all catalytic sites. The flexibility of Met45 ($\beta 5$) affords accommodation of larger P1 sites (isopropyl in omuralide, and cyclohexenyl ring in salinosporamide A). Furthermore, the bulkier P1 group in salinosporamide A allows for additional hydrophobic interactions, helping explain at least in part the enhanced potency of salinosporamide A over omuralide [22,34], and also the affinity to $\beta 2$ which presents a larger S1 pocket, consistent to salinosporamide A's inhibition of tryptic activity as opposed to bortezomib [33]. As shown in Figure 3d, the rather small β -lactone inhibitor occupies only specificity pockets S1 and S2. Yet, it represents a equipotent antitumor agent compared to bortezomib [36].

As mentioned for bortezomib, the P2 group projects into empty space. Therefore there is sufficient space to accommodate larger side chains as exemplified by the cinnabaramides [28]. Most important, P2 of β -lactone inhibitors appears to be fundamental in determining if binding is reversible or irreversible. Although omuralide has been reported to bind to the proteasome irreversibly [20], based on a synthetic analog, binding of omuralide and of the deschloro analog salinosporamide B should be slowly reversible [34]. After salinosporamide A becomes covalently tethered to Thr1, the resulting C3 hydroxyl displaces the C13 chlorine to yield an irreversibly bound adduct, since the newly formed tetrahydrofuran ring i) blocks water attack on the ester bond preventing hydrolysis, ii) engages C3O and circumvents reformation of the β -lactone, and iii) the resulting protonated state of Thr1NH₂ results in inactivation of its catalytic activity (Fig. 3b/3f).

Therapeutic Outlook

Proteasome inhibitors have been instrumental to our fundamental understanding and appreciation of the ubiquitin-proteasome system and are now rapidly emerging as important new treatment options in cancer. A new generation of proteasome inhibitors headed by salinosporamide A and PR-171 are presently being evaluated clinically and may offer alternative treatment to patients intolerant or whose disease is refractory to bortezomib. Comparative pre-clinical studies of these irreversible inhibitors as single agents suggest reduced toxicity and improved pathology [37,38], while combination therapy of salinosporamide A and bortezomib affords synergistic anti-multiple myeloma activity at

reduced doses without the toxicity and resistance attributed to bortezomib alone [39]. The landscape of proteasome inhibitor-based therapeutics is quickly evolving with promise in other diseases beyond clinical oncology and represents an exciting example of translational medicine.

Primary resistance, as exemplified by bortezomid's ineffectiveness against some solid tumors, as well as acquired resistance may represent future hurdles for the wider applicability of proteasome inhibitors [5]. Therefore further studies aimed to understand underlying mechanisms as well as the development of second-generation drugs are imperative. In this context, new proteasome inhibitors were reported during the production of this article. The plant pathogen virulence factor syringolin A from *Pseudomonas syringae* pv. *syringae* shows a novel mechanism of covalent binding to the proteasome representing a new class of inhibitors containing a reactive α,β -unsaturated carbonyl group that also includes glidobactin A (Fig. 2) [40]. Moreover, the fungal peptide aldehyde fellutamide B, a known inducer of nerve growth factor (NGF), was reported to inhibit the proteasome [41]. The authors also show that other proteasome inhibitors induce production and secretion of NFG, suggesting that targeting the proteasome may aid in the treatment of neurodegenerative diseases. Together, these recent additions provide further examples of proteasome inhibition in nature as well as emphasize the vast therapeutic potential of small molecule proteasome inhibitors.

Acknowledgments

This work was supported by a grant from the National Institutes of Health (CA127622 to B.S.M.). A.S.E. is a Tularik postdoctoral fellow of the Life Sciences Research Foundation.

References and recommended reading

Papers of particular interest, published within the annual period of review, have been highlighted as:

- of special interest
- of outstanding interest

1. Goldberg AL. Protein degradation and protection against misfolded or damaged proteins. *Nature* 2003;426:895–899. [PubMed: 14685250]
2. Adams J. The proteasome: a suitable antineoplastic target. *Nat. Rev. Cancer* 2004;4:349–360. [PubMed: 15122206]
3. Goldberg AL. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. *Biochem. Soc. Trans* 2007;35:12–17. [PubMed: 17212580] • This refreshing review article by Alfred Goldberg shares his personal insight over the past 40 years on the discovery, function and clinical promise of the proteasome.
4. Orlowski RZ, Zeger EL. Targeting the proteasome as a therapeutic strategy against haematological malignancies. *Expert Opin. Invest. Drugs* 2006;15:117–130.
5. Orlowski RZ, Kuhn DJ. Proteasome inhibitors in cancer therapy: Lessons from the first decade. *Clin. Cancer Res* 2008;14:1649–1657. [PubMed: 18347166]
6. Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider J, Sterz J, Jakob C, Sezer O. Proteasome as an emerging therapeutic target in cancer. *Curr. Pharm. Design* 2007;13:471–485.
7. Meiners S, Ludwig A, Stangl V, Stangl K. Proteasome inhibitors: Poisons and remedies. *Med. Res. Rev* 2008;28:309–327. [PubMed: 17880010]
8. Borissenko L, Groll M. 20S proteasome and its inhibitors: Crystallographic knowledge for drug development. *Chem. Rev* 2007;107:687–717. [PubMed: 17316053] •• This review article provides a comprehensive account of the proteasome and its inhibitors based on a structural perspective.
9. Vinitzky A, Michaud C, Powers JC, Orlowski M. Inhibition of the chymotrypsin-like activity of the pituitary multicatalytic proteinase complex. *Biochemistry* 1992;31:9421–9428. [PubMed: 1356435]

10. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. Crystal structure of the 20S proteasome from the archaeon *T. acidophilum* at 3.4 Å resolution. *Science* 1995;268:533–539. [PubMed: 7725097]
11. Palmer JT, Rasnick D, Klaus JL, Bromme D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. *J. Med. Chem* 1995;38:3193–3196. [PubMed: 7650671]
12. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, Klunder JM, Ma YT, Plamondon L, Stein RL. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids. *Bioorg. Med. Chem. Lett* 1998;8:333–338. [PubMed: 9871680]
13. Meng L, Mohan R, Kwok BH, Eloffson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-inflammatory activity. *Proc. Natl. Acad. Sci. U.S.A* 1999;96:10403–10408. [PubMed: 10468620]
14. Williamson MJ, Blank JL, Bruzzese FJ, Cao Y, Daniels JS, Dick LR, Labutti J, Mazzola AM, Patil AD, Reimer CL, et al. Comparison of biochemical and biological effects of ML858 (salinosporamide A) and bortezomib. *Mol. Cancer Ther* 2006;5:3052–3061. [PubMed: 17172407]
15. Dorsey BD, Iqbal M, Chatterjee S, Menta E, Bernardini R, Bernareggi A, Cassara PG, D'Arasmo G, Ferretti E, De Munari S, et al. Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. *J. Med. Chem* 2008;51:1068–1072. [PubMed: 18247547]
16. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, et al. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. *Blood* 2008;111:2765–2775. [PubMed: 18057228]
17. Groll M, Kim KB, Kairies N, Huber R, Crews CM. Crystal structure of epoxomicin:20S proteasome reveals a molecular basis for selectivity of α' , β' -epoxyketone proteasome inhibitors. *J. Am. Chem. Soc* 2000;122:1237–1238.
18. Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. *Cancer Res* 2007;67:6383–6391. [PubMed: 17616698]
19. Omura S, Matsuzaki K, Fujimoto T, Kosuge K, Furuya T, Fujita S, Nakagawa A. Structure of lactacystin, a new microbial metabolite which induces differentiation of neuroblastoma cells. *J. Antibiot* 1991;44:117–118. [PubMed: 2001981]
20. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. *Science* 1995;268:726–731. [PubMed: 7732382]
21. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. *J. Mol. Med* 2003;81:235–245. [PubMed: 12700891]
22. Feling RH, Buchanan GO, Mincer TJ, Kauffman CA, Jensen PR, Fenical W. Salinosporamide A, an antitumor proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus *Salinispora*. *Angew. Chem. Int. Ed* 2003;115:369–371.
23. Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B, Deyanat-Yazdi G, Mai B, Jensen PR, Fenical W, et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. *J. Med. Chem* 2005;48:3684–3687. [PubMed: 15916417]
24. Williams PG, Buchanan GO, Feling RH, Kauffman CA, Jensen PR, Fenical W. New cytotoxic salinosporamides from the marine actinomycete *Salinispora tropica*. *J. Org. Chem* 2005;70:6196–6203. [PubMed: 16050677]
25. Reddy LR, Fournier JF, Reddy BVS, Corey EJ. An efficient, stereocontrolled synthesis of a potent omuralide-salinosporin hybrid for selective proteasome inhibition. *J. Am. Chem. Soc* 2005;127:8974–8976. [PubMed: 15969573]
26. McGlinchey RP, Nett M, Eustaquio AS, Asolkar RN, Fenical W, Moore BS. Engineered biosynthesis of antiprotealide and other unnatural salinosporamide proteasome inhibitors. *J. Am. Chem* 2008;130:7822–7823. • Together with reference 27, this paper describes the engineered biosynthesis of diverse salinosporamide-based proteasome inhibitors.
27. Eustáquio AS, Moore BS. Mutasynthesis of fluorosalinosporamide, a potent and reversible inhibitor of the proteasome. *Angew. Chem. Int. Ed* 2008;47:3936–3938.

28. Stadler M, Bitzer J, Mayer-Bartschmid A, Müller H, Benet-Buchholz J, Gantner F, Tichy H-V, Reinemer P, Baco KB. Cinnabaramides A-G: analogues of lactacystin and salinosporamide from a terrestrial streptomycete. *J. Nat. Prod* 2007;70:246–252. [PubMed: 17249727]
29. Groll M, Larionov OV, Huber R, de Meijere A. Inhibitor-binding mode of homobelactosin C to proteasomes: New insights into class I MHC ligand generation. *Proc. Natl. Acad. Sci. U.S.A* 2006;103:4576–4579. [PubMed: 16537370]
30. Koguchi Y, Kohno J, Nishio M, Takahashi K, Okuda T, Ohnuki T, Komatsubara S. TMC-95A, B, C, and D, novel proteasome inhibitors produced by *Apiospora montagnei* Sacc. TC 1093. Taxonomy, production, isolation and biological activities. *J. Antibiot* 2000;53:105–109. [PubMed: 10805568]
31. Groll M, Gotz M, Kaiser M, Weyher E, Moroder L. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. *Chem. Biol* 2006;13:607–614. [PubMed: 16793518]
32. Udvary DW, Zeigler L, Asolkar RN, Singan V, Lapidus A, Fenical W, Jensen PR, Moore BS. Genome sequencing reveals complex secondary metabolome in the marine actinomycete *Salinispora tropica*. *Proc. Natl. Acad. Sci. U.S.A* 2007;104:10376–10381. [PubMed: 17563368]
33. Groll M, Berkers CR, Ploegh HL, Ovaas H. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. *Structure* 2006;14:451–456. [PubMed: 16531229] •• This report reveals specificity and binding mode of marketed bortezomib (Velcade®) at the molecular level. Knowledge gained herein could be used for the rational design of new agents.
34. Groll M, Huber R, Potts BCM. Crystal structures of salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding. *J. Am. Chem. Soc* 2006;128:5136–5141. [PubMed: 16608349] •• Likewise, the molecular basis of proteasome inhibition by salinosporamide A, currently in human clinical trials, is discussed.
35. Chauhan D, Catley L, Li GL, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. *Cancer Cell* 2005;8:407–419. [PubMed: 16286248]
36. Chauhan D, Hideshima T, Anderson KC. A novel proteasome inhibitor NPI-0052 as an anticancer therapy. *Br. J. Cancer* 2006;95:961–965. [PubMed: 17047643]
37. Ahn KS, Sethi G, Chao TH, Neuteboom STC, Chaturvedi MM, Palladino MA, Younes A, Aggarwal BB. Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappa B-regulated gene products. *Blood* 2007;110:2286–2295. [PubMed: 17609425]
38. Miller CP, Ban K, Dujka ME, McConkey DJ, Munsell M, Palladino MA, Chandra J. NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemic cells. *Blood* 2007;110:267–277. [PubMed: 17356134]
39. Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. *Blood* 2008;111:1654–1664. [PubMed: 18006697]
40. Groll M, Schellenberg B, Bachmann AS, Archer CR, Huber R, Powell TK, Lindow S, Kaiser M, Dudler R. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. *Nature* 2008;452:755–758. [PubMed: 18401409] •• A new mechanism of proteasome inhibition involving the virulence factor syringolin A from the plant pathogen *Pseudomonas syringae* was recently described.
41. Hines J, Groll M, Fahnestock M, Crews CM. Proteasome inhibition by fellutamide A induces nerve growth factor synthesis. *Chem. Biol* 2008;15:501–512. [PubMed: 18482702] •• The discovery that fellutamide induces nerve growth factor secretion by a mechanism involving proteasome inhibition suggests new therapeutic applications by these inhibitors.
42. Landis-Piwowar KR, Milacic V, Chen D, Yang H, Zhao Y, Chan TH, Yan B, Dou QP. The proteasome as a potential target for novel anticancer drugs and chemosensitizers. *Drug Resist. Updat* 2006;9:263–273. [PubMed: 17197231]
43. Tsukamoto S, Yokosawa H. Natural products inhibiting the ubiquitin-proteasome proteolytic pathway, a target for drug development. *Curr. Med. Chem* 2006;13:745–754. [PubMed: 16611064]

44. DeLano, WL. The PyMOL Molecular Graphics System. 2002. <http://www.pymol.org>.

Figure 1. The ubiquitin-proteasome pathway

Intracellular proteins (e.g. phosphorylated through signaling pathways or misfolded) are targeted for degradation by a covalently bound ubiquitin tag [2]. Ubiquitylation is catalyzed by a multi-enzymatic system consisting of E1 (ubiquitin-activating enzyme), E2 (conjugating) and E3 (ligases). The 26S proteasome is an ATP-dependent protease complex comprised of a 20S catalytic core (organized into four stacked rings of seven subunits each, i.e. $\alpha_7\beta_7\beta_7\alpha_7$) and two 19S regulatory caps. 19S caps are responsible for recognition of ubiquitinated proteins (lid) and also contain ATPase activity (base) required for linearization of large proteins facilitating their entry in the catalytic core. Three β -subunits (β_1 , β_2 , β_5) are responsible for the different enzymatic activities of the proteasome and are differentially inhibited by small molecule inhibitors such as bortezomib and salinosporamide A. Figure adapted from reference [42].

Figure 2. Representative structures of proteasome inhibitors

Electrophilic functional groups are depicted in red. See text for further discussion.

Figure 3. Inhibitory mechanism of synthetic dipeptide boronic acid bortezomib and β -lactone natural product salinosporamide

Close-up view of bortezomib [33] (**a**) and salinosporamide A [34] (**b**) bound to Thr1 in the $\beta 5$ active site of yeast 20S proteasome (PDB codes 2F16 and 2FAK, respectively). Hydrogen bonds are depicted as orange dashes and waters as red dots. (**c**, **d**) Surface representation showing the same view for each inhibitor as well as occupancy in specificity pockets S1, S2 and S3. (**e**) Reversible inhibitory mechanism of bortezomib is dictated by the boronic acid group [43]. (**f**) Chlorine is key for irreversible binding of salinosporamide A [34]. Figure panels a-d were generated with PyMol [44].